Form 4: Serge Saxonov, CEO of 10x Genomics, Reports Changes in Beneficial Ownership

Serge Saxonov, CEO of 10x Genomics, filed a Form 4 detailing the acquisition of restricted stock units and changes in his beneficial ownership of Class A Common Stock.

Summary

• Serge Saxonov, the CEO of 10x Genomics, filed a Form 4 with the SEC.
• The filing reports changes in his beneficial ownership of the company's Class A Common Stock.
• On March 21, 2024, Saxonov acquired 88,854 restricted stock units (RSUs).
• These RSUs vest quarterly, with 1/16th vesting on each quarterly anniversary from February 21, 2024, contingent upon his continued service.
• Following the reported transaction, Saxonov directly owns 894,518 shares of Class A Common Stock.
• He also has indirect ownership through several trusts: Andromeda Trust (27 shares), Sirius Trust (870 shares), Y/S Descendants' Trust (213,250 shares), and Y/S Pot Trust (22,570 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reflecting changes in ownership. The acquisition of RSUs can be seen as a slightly positive sign of the CEO's commitment.

Positives

• The acquisition of RSUs suggests continued confidence in the company's future by its CEO.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs implies a multi-year commitment from the CEO.

Industry Context

Form 4 filings are routine disclosures for company insiders and provide transparency into their transactions in the company's stock. This filing indicates the CEO's continued investment in 10x Genomics.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of RSUs as a positive signal.

Key Dates